Catrina Crisp, MD
Urogynecology and Reconstructive Pelvic Surgery · Cincinnati, OHNPI 1477675874
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,260 of the $2,533 with a category attached, or 89.2%. 16 manufacturers reported payments, led by Medtronic at 50.9% of the total. 2025 is the largest year on record at $821, 2.5 times the $324 reported in 2019. That places this record below the midpoint for urogynecology and reconstructive pelvic surgery clinicians in OH, where the typical reported total is $3,689.
Across 55 payments — averaging $46.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Boston Scientific$232
- AbbVie$200
- Heron Therapeutics, Inc.$137
- Astellas Pharma US Inc$133
- Axonics, Inc.$130
- plus $412 from 10 others
Across 35 payments — averaging $1480.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$20K
- Urovant Sciences Inc$20K
- Sumitomo Pharma America, Inc.$12K
What the payments were for
- Travel & lodging$2299%
- Food & beverage$2,26089%
- Gifts$442%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 18 | $1,288 |
| Boston Scientific | 5 | $232 |
| AbbVie(2 entities) | 5 | $200 |
| Heron Therapeutics, Inc. | 2 | $137 |
| Astellas Pharma US Inc | 8 | $133 |
| Axonics, Inc. | 3 | $130 |
| Intuitive Surgical | 1 | $93 |
| Laborie Medical Technologies Corp. | 2 | $81 |
| Coloplast | 3 | $57 |
| Caldera Medical, Inc | 1 | $44 |
| Urovant Sciences Inc | 2 | $38 |
| Rochester Medical Corporation | 1 | $26 |
| Dexcom, Inc. | 1 | $22 |
| Pacira Pharmaceuticals Incorporated | 1 | $20 |
| Novo Nordisk | 1 | $19 |
| Therapeuticsmd, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,533 in reported general payments places this provider in the 35th percentile of 60 urogynecology and reconstructive pelvic surgery providers in Ohio.
See all urogynecology and reconstructive pelvic surgery providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 294 | $216,177 |
| GemtesaVibegron | 86 | $58,677 |
| Solifenacin Succinate | 359 | $15,886 |
| Estradiol | 220 | $13,020 |
| Trimethoprim | 149 | $8,294 |
| Mirabegron ErMirabegron | 15 | $6,979 |
| Methenamine Hippurate | 86 | $6,037 |
| Trospium Chloride ErTrospium Chloride | 27 | $3,607 |
| Clobetasol Propionate | 45 | $2,802 |
| Trospium Chloride | 80 | $2,728 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 117 | $2,189 |
| Fosfomycin Tromethamine | 11 | $1,876 |
| Cephalexin | 62 | $575 |
| Nystatin-TriamcinoloneNystatin/Triamcinolone Acet | 11 | $381 |
| Nystatin | 12 | $247 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $133 | $216,177294 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 60 urogynecology and reconstructive pelvic surgery providers in Ohio.
Other urogynecology and reconstructive pelvic surgery in Cincinnati
- Anne StachowiczCincinnati$10K
- Anna ZdroikCincinnati$8K
- Jennifer YeungCincinnati$7K
- Kelsey LewisCincinnati$2K
- Steven KleemanCincinnati$820
- Aparna ShahCincinnati$753
- Costas ApostolisStrongsville$982K
- Mickey KarramWest Chester$127K
- Sangeeta MahajanMayfield Hts$48K
- Emily SlopnickCleveland$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.